항체약물접합체 시장 : 작용기서, 약제, 기술, 적응증, 최종사용자별 - 세계 예측(2025-2030년)

The Antibody Drug Conjugate Market was valued at USD 5.60 billion in 2023, expected to reach USD 6.48 billion in 2024, and is projected to grow at a CAGR of 16.12%, to USD 15.96 billion by 2030.

Antibody Drug Conjugates (ADCs) represent a cutting-edge approach in targeted cancer therapy, leveraging the specificity of monoclonal antibodies to deliver cytotoxic agents directly to cancer cells, thus minimizing systemic exposure and reducing side effects. The necessity of ADCs lies in their ability to enhance the therapeutic index by precisely targeting cancer cells, providing a substantial advantage over traditional chemotherapy. ADCs find application predominantly in oncology, but potential uses in autoimmune and infectious diseases are under exploration. The end-use scope spans hospitals, specialized cancer treatment centers, and research institutes. Market growth is driven by increased cancer prevalence, advancements in bioconjugation technologies, and rising investments in R&D. Key growth factors also include a growing pipeline of ADCs in clinical trials and a better understanding of tumor biology. Notable opportunities exist in developing ADCs with novel mechanisms and improved linker technologies to enhance stability and efficacy. There is also potential for expanding the use of ADCs in non-oncological fields. However, challenges such as high developmental costs, complex manufacturing processes, and regulatory hurdles pose significant limitations. The market also faces competition from alternative therapies like CAR-T cell therapy. Innovations can focus on enhancing payload diversity, improving targeting accuracy, and reducing off-target effects. Exploring ADC combinations with immune checkpoint inhibitors offers another research avenue. The ADC market is characterized by rapid technological advancements and collaborative partnerships, emphasizing a trend towards personalized medicine. Companies should prioritize strategic collaborations and licensing agreements to leverage biopharmaceutical advancements. Overall, expanding the therapeutic applicability of ADCs beyond oncology and refining the delivery mechanisms are vital for sustained market growth, ensuring ADCs remain at the forefront of precision medicine innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Drug Conjugate Market

The Antibody Drug Conjugate Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer worldwide
  • Growth in clinical trial activities and robust product pipeline
  • Government support and initiatives encouraging research on cancer
• Market Restraints
  • High manufacturing cost of ADC and incidences of product recalls
• Market Opportunities
  • Increasing investment in biopharma R&D and introduction of novel ADCs
  • Adoption of advanced technologies for developing ADC
• Market Challenges
  • Complexity in manufacturing of ADCs

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Drug Conjugate Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Drug Conjugate Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Drug Conjugate Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Drug Conjugate Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Drug Conjugate Market

A detailed market share analysis in the Antibody Drug Conjugate Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Drug Conjugate Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Drug Conjugate Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Mechanism of Action, market is studied across CD30 Antibodies and ErbB2 Antibodies.
• Based on Drugs, market is studied across Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, and Trodelvy.
• Based on Technology, market is studied across Cleavable Linker, Linkerless, and Non-Cleavable Linker.
• Based on Indication, market is studied across Blood Cancer, Breast Cancer, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.
• Based on End User, market is studied across Academic Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals, and Specialized Cancer Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Alaska, California, Florida, Illinois, Massachusetts, Michigan, Montana, Nevada, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer worldwide
    • 5.1.1.2. Growth in clinical trial activities and robust product pipeline
    • 5.1.1.3. Government support and initiatives encouraging research on cancer
  • 5.1.2. Restraints
    • 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
    • 5.1.3.2. Adoption of advanced technologies for developing ADC
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in manufacturing of ADCs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
  • 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
  • 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
  • 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
  • 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibody Drug Conjugate Market, by Mechanism of Action

• 6.1. Introduction
• 6.2. CD30 Antibodies
• 6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

• 7.1. Introduction
• 7.2. Adcetris
• 7.3. Blenrep
• 7.4. Enhertu
• 7.5. Kadcyla
• 7.6. Padcev
• 7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

• 8.1. Introduction
• 8.2. Cleavable Linker
• 8.3. Linkerless
• 8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

• 9.1. Introduction
• 9.2. Blood Cancer
• 9.3. Breast Cancer
• 9.4. Lymphoma
• 9.5. Multiple Myeloma
• 9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

• 10.1. Introduction
• 10.2. Academic Research Institutes
• 10.3. Biopharmaceutical & Biotechnology Companies
• 10.4. Hospitals
• 10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
  • 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
  • 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
  • 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
  • 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
  • 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
  • 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
  • 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
  • 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
  • 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
  • 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. ADC Therapeutics SA
• 4. Ambrx Biopharma Inc.
• 5. Amgen Inc.
• 6. Astellas Pharma Inc.
• 7. AstraZeneca PLC
• 8. Bayer AG
• 9. BioNTech SE
• 10. Bristol-Myers Squibb Company
• 11. Byondis B.V.
• 12. Celldex Therapeutics Inc.
• 13. Creative Biolabs, Inc.
• 14. Daiichi Sankyo Company, Limited
• 15. Eisai Co., Ltd.
• 16. F. Hoffmann-La Roche Ltd.
• 17. Gilead Sciences, Inc.
• 18. GlaxoSmithKline PLC
• 19. Heidelberg Pharma AG
• 20. ImmunoGen, Inc.
• 21. Innate Pharma SA
• 22. Innovent Biologics, Inc.
• 23. Lonza Group Ltd.
• 24. MacroGenics, Inc.
• 25. MediLink Therapeutics
• 26. Merck KGaA
• 27. Mersana Therapeutics, Inc.
• 28. Novartis AG
• 29. Oxford Biotherapeutics Limited
• 30. Pfizer, Inc.
• 31. Pheon Therapeutics Ltd.
• 32. Piramal Pharma Limited
• 33. Recipharm AB
• 34. Sanofi S.A.
• 35. Sorrento Therapeutics, Inc.
• 36. Tagworks Pharmaceuticals BV
• 37. Takeda Pharmaceutical Company Limited
• 38. Tubulis GmbH
• 39. Zymeworks Inc.